How Mutation Status Affects Individualization of Treatment in mCRC

October 28, 2016
Maria Ignez Braghiroli, MD

Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses how mutation status effects individualization of treatment in metastatic colorectal cancer (mCRC).